NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $15.62 -1.05 (-6.30%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$15.91 +0.29 (+1.86%) As of 04/4/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tectonic Therapeutic Stock (NASDAQ:TECX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tectonic Therapeutic alerts:Sign Up Key Stats Today's Range$15.20▼$16.5550-Day Range$15.62▼$54.8452-Week Range$15.00▼$61.07Volume172,067 shsAverage Volume168,860 shsMarket Capitalization$291.52 millionP/E RatioN/ADividend YieldN/APrice Target$77.75Consensus RatingBuy Company OverviewTectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Read More… Remove Ads Tectonic Therapeutic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreTECX MarketRank™: Tectonic Therapeutic scored higher than 62% of companies evaluated by MarketBeat, and ranked 331st out of 902 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingTectonic Therapeutic has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTectonic Therapeutic has only been the subject of 1 research reports in the past 90 days.Read more about Tectonic Therapeutic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tectonic Therapeutic are expected to grow in the coming year, from ($8.31) to ($5.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 7.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tectonic Therapeutic's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.22% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tectonic Therapeutic has recently decreased by 6.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.22% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tectonic Therapeutic has recently decreased by 6.59%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News SentimentN/A News SentimentTectonic Therapeutic has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,249,942.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.20% of the stock of Tectonic Therapeutic is held by insiders.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Email Address TECX Stock News HeadlinesAnalysts Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $77.75March 28, 2025 | americanbankingnews.comTectonic Therapeutic files to sell 3.69M shares of common stock for holdersMarch 27, 2025 | markets.businessinsider.comCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see this footage.) A lot of people believe the U.S. government is hiding aliens at the highly classified U.S. Air Force facility in Nevada known as “Area 51.”April 6, 2025 | Brownstone Research (Ad)Tectonic Therapeutic Inc (TECX) Reports Q4 2024 Net Loss of $12. ...March 20, 2025 | gurufocus.comTectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent ...March 20, 2025 | gurufocus.comTectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 20, 2025 | globenewswire.comTectonic Therapeutic, Inc. (TECX): Among the Most Expensive Stocks Insiders Are Buying RecentlyFebruary 22, 2025 | msn.comTectonic Therapeutic to Participate in March Investor ConferencesFebruary 20, 2025 | markets.businessinsider.comSee More Headlines TECX Stock Analysis - Frequently Asked Questions How have TECX shares performed this year? Tectonic Therapeutic's stock was trading at $46.17 at the start of the year. Since then, TECX stock has decreased by 66.2% and is now trading at $15.62. View the best growth stocks for 2025 here. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic (NASDAQ:TECX) released its quarterly earnings data on Thursday, March, 20th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.55. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tectonic Therapeutic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tectonic Therapeutic investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/20/2025Today4/06/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TECX Previous SymbolNASDAQ:TECX CIK1681087 Webwww.avrobio.com Phone617-914-8420FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$77.75 High Stock Price Target$101.00 Low Stock Price Target$65.00 Potential Upside/Downside+397.8%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$12.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.53% Return on Assets-31.97% Debt Debt-to-Equity RatioN/A Current Ratio9.39 Quick Ratio9.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book7.33Miscellaneous Outstanding Shares18,663,000Free Float13,396,000Market Cap$291.52 million OptionableN/A Beta2.87 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:TECX) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.